Browse CARM1

Summary
SymbolCARM1
Namecoactivator-associated arginine methyltransferase 1
Aliases PRMT4; Histone-arginine methyltransferase CARM1
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus. Cytoplasm. Note=Mainly nuclear during the G1, S and G2 phases of the cell cycle. Cytoplasmic during mitosis, after breakup of the nuclear membrane.
Domain PF11531 Coactivator-associated arginine methyltransferase 1 N terminal
Function

Methylates (mono- and asymmetric dimethylation) the guanidino nitrogens of arginyl residues in several proteins involved in DNA packaging, transcription regulation, pre-mRNA splicing, and mRNA stability. Recruited to promoters upon gene activation together with histone acetyltransferases from EP300/P300 and p160 families, methylates histone H3 at 'Arg-17' (H3R17me), forming mainly asymmetric dimethylarginine (H3R17me2a), leading to activate transcription via chromatin remodeling. During nuclear hormone receptor activation and TCF7L2/TCF4 activation, acts synergically with EP300/P300 and either one of the p160 histone acetyltransferases NCOA1/SRC1, NCOA2/GRIP1 and NCOA3/ACTR or CTNNB1/beta-catenin to activate transcription. During myogenic transcriptional activation, acts together with NCOA3/ACTR as a coactivator for MEF2C. During monocyte inflammatory stimulation, acts together with EP300/P300 as a coactivator for NF-kappa-B. Acts as coactivator for PPARG, promotes adipocyte differentiation and the accumulation of brown fat tissue. Plays a role in the regulation of pre-mRNA alternative splicing by methylation of splicing factors. Also seems to be involved in p53/TP53 transcriptional activation. Methylates EP300/P300, both at 'Arg-2142', which may loosen its interaction with NCOA2/GRIP1, and at 'Arg-580' and 'Arg-604' in the KIX domain, which impairs its interaction with CREB and inhibits CREB-dependent transcriptional activation. Also methylates arginine residues in RNA-binding proteins PABPC1, ELAVL1 and ELAV4, which may affect their mRNA-stabilizing properties and the half-life of their target mRNAs.

> Gene Ontology
 
Biological Process GO:0000075 cell cycle checkpoint
GO:0000077 DNA damage checkpoint
GO:0000082 G1/S transition of mitotic cell cycle
GO:0001501 skeletal system development
GO:0003416 endochondral bone growth
GO:0003417 growth plate cartilage development
GO:0003419 growth plate cartilage chondrocyte proliferation
GO:0003420 regulation of growth plate cartilage chondrocyte proliferation
GO:0006479 protein methylation
GO:0006977 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest
GO:0007050 cell cycle arrest
GO:0007093 mitotic cell cycle checkpoint
GO:0007346 regulation of mitotic cell cycle
GO:0007568 aging
GO:0008213 protein alkylation
GO:0009755 hormone-mediated signaling pathway
GO:0010721 negative regulation of cell development
GO:0010948 negative regulation of cell cycle process
GO:0010975 regulation of neuron projection development
GO:0010977 negative regulation of neuron projection development
GO:0014074 response to purine-containing compound
GO:0016358 dendrite development
GO:0016570 histone modification
GO:0016571 histone methylation
GO:0018195 peptidyl-arginine modification
GO:0018216 peptidyl-arginine methylation
GO:0019919 peptidyl-arginine methylation, to asymmetrical-dimethyl arginine
GO:0030330 DNA damage response, signal transduction by p53 class mediator
GO:0030518 intracellular steroid hormone receptor signaling pathway
GO:0030520 intracellular estrogen receptor signaling pathway
GO:0030522 intracellular receptor signaling pathway
GO:0031345 negative regulation of cell projection organization
GO:0031570 DNA integrity checkpoint
GO:0031571 mitotic G1 DNA damage checkpoint
GO:0032091 negative regulation of protein binding
GO:0032259 methylation
GO:0033143 regulation of intracellular steroid hormone receptor signaling pathway
GO:0033146 regulation of intracellular estrogen receptor signaling pathway
GO:0034969 histone arginine methylation
GO:0034970 histone H3-R2 methylation
GO:0034971 histone H3-R17 methylation
GO:0035246 peptidyl-arginine N-methylation
GO:0035247 peptidyl-arginine omega-N-methylation
GO:0035265 organ growth
GO:0042770 signal transduction in response to DNA damage
GO:0043393 regulation of protein binding
GO:0043401 steroid hormone mediated signaling pathway
GO:0043414 macromolecule methylation
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044773 mitotic DNA damage checkpoint
GO:0044774 mitotic DNA integrity checkpoint
GO:0044783 G1 DNA damage checkpoint
GO:0044819 mitotic G1/S transition checkpoint
GO:0044843 cell cycle G1/S phase transition
GO:0045444 fat cell differentiation
GO:0045598 regulation of fat cell differentiation
GO:0045600 positive regulation of fat cell differentiation
GO:0045665 negative regulation of neuron differentiation
GO:0045786 negative regulation of cell cycle
GO:0045787 positive regulation of cell cycle
GO:0045930 negative regulation of mitotic cell cycle
GO:0046620 regulation of organ growth
GO:0046683 response to organophosphorus
GO:0048545 response to steroid hormone
GO:0048638 regulation of developmental growth
GO:0048705 skeletal system morphogenesis
GO:0050768 negative regulation of neurogenesis
GO:0050773 regulation of dendrite development
GO:0051098 regulation of binding
GO:0051100 negative regulation of binding
GO:0051216 cartilage development
GO:0051591 response to cAMP
GO:0051961 negative regulation of nervous system development
GO:0060348 bone development
GO:0060349 bone morphogenesis
GO:0060350 endochondral bone morphogenesis
GO:0060351 cartilage development involved in endochondral bone morphogenesis
GO:0061035 regulation of cartilage development
GO:0061448 connective tissue development
GO:0071156 regulation of cell cycle arrest
GO:0071158 positive regulation of cell cycle arrest
GO:0071383 cellular response to steroid hormone stimulus
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0072331 signal transduction by p53 class mediator
GO:0072395 signal transduction involved in cell cycle checkpoint
GO:0072401 signal transduction involved in DNA integrity checkpoint
GO:0072413 signal transduction involved in mitotic cell cycle checkpoint
GO:0072422 signal transduction involved in DNA damage checkpoint
GO:0072431 signal transduction involved in mitotic G1 DNA damage checkpoint
GO:0090068 positive regulation of cell cycle process
GO:0098868 bone growth
GO:1901987 regulation of cell cycle phase transition
GO:1901988 negative regulation of cell cycle phase transition
GO:1901990 regulation of mitotic cell cycle phase transition
GO:1901991 negative regulation of mitotic cell cycle phase transition
GO:1902400 intracellular signal transduction involved in G1 DNA damage checkpoint
GO:1902402 signal transduction involved in mitotic DNA damage checkpoint
GO:1902403 signal transduction involved in mitotic DNA integrity checkpoint
GO:1902415 regulation of mRNA binding
GO:1902806 regulation of cell cycle G1/S phase transition
GO:1902807 negative regulation of cell cycle G1/S phase transition
GO:1903010 regulation of bone development
GO:1905214 regulation of RNA binding
GO:2000027 regulation of organ morphogenesis
GO:2000045 regulation of G1/S transition of mitotic cell cycle
GO:2000134 negative regulation of G1/S transition of mitotic cell cycle
GO:2000171 negative regulation of dendrite development
Molecular Function GO:0003713 transcription coactivator activity
GO:0008013 beta-catenin binding
GO:0008168 methyltransferase activity
GO:0008170 N-methyltransferase activity
GO:0008276 protein methyltransferase activity
GO:0008469 histone-arginine N-methyltransferase activity
GO:0008757 S-adenosylmethionine-dependent methyltransferase activity
GO:0016273 arginine N-methyltransferase activity
GO:0016274 protein-arginine N-methyltransferase activity
GO:0016741 transferase activity, transferring one-carbon groups
GO:0030374 ligand-dependent nuclear receptor transcription coactivator activity
GO:0035242 protein-arginine omega-N asymmetric methyltransferase activity
GO:0035642 histone methyltransferase activity (H3-R17 specific)
GO:0042054 histone methyltransferase activity
GO:0042393 histone binding
GO:0070577 lysine-acetylated histone binding
Cellular Component GO:0005667 transcription factor complex
GO:0044798 nuclear transcription factor complex
GO:0090575 RNA polymerase II transcription factor complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-2426168: Activation of gene expression by SREBF (SREBP)
R-HSA-1368108: BMAL1
R-HSA-3247509: Chromatin modifying enzymes
R-HSA-4839726: Chromatin organization
R-HSA-400253: Circadian Clock
R-HSA-1266738: Developmental Biology
R-HSA-535734: Fatty acid, triacylglycerol, and ketone body metabolism
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-1592230: Mitochondrial biogenesis
R-HSA-1852241: Organelle biogenesis and maintenance
R-HSA-1989781: PPARA activates gene expression
R-HSA-3214858: RMTs methylate histone arginines
R-HSA-1368082: RORA activates gene expression
R-HSA-1655829: Regulation of cholesterol biosynthesis by SREBP (SREBF)
R-HSA-400206: Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
R-HSA-6791312: TP53 Regulates Transcription of Cell Cycle Genes
R-HSA-6804114: TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
R-HSA-3700989: Transcriptional Regulation by TP53
R-HSA-2151201: Transcriptional activation of mitochondrial biogenesis
R-HSA-381340: Transcriptional regulation of white adipocyte differentiation
R-HSA-2032785: YAP1- and WWTR1 (TAZ)-stimulated gene expression
Summary
SymbolCARM1
Namecoactivator-associated arginine methyltransferase 1
Aliases PRMT4; Histone-arginine methyltransferase CARM1
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CARM1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolCARM1
Namecoactivator-associated arginine methyltransferase 1
Aliases PRMT4; Histone-arginine methyltransferase CARM1
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CARM1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.13; FDR: 0.04630 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolCARM1
Namecoactivator-associated arginine methyltransferase 1
Aliases PRMT4; Histone-arginine methyltransferase CARM1
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CARM1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0360.883
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1880.933
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0730.965
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1070.757
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0160.993
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2670.917
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0250.943
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1450.928
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2370.892
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5770.662
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.130.56
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0240.67
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CARM1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.12.78.40.12
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.13.47.70.176
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCARM1
Namecoactivator-associated arginine methyltransferase 1
Aliases PRMT4; Histone-arginine methyltransferase CARM1
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CARM1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCARM1
Namecoactivator-associated arginine methyltransferase 1
Aliases PRMT4; Histone-arginine methyltransferase CARM1
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CARM1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CARM1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCARM1
Namecoactivator-associated arginine methyltransferase 1
Aliases PRMT4; Histone-arginine methyltransferase CARM1
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CARM1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCARM1
Namecoactivator-associated arginine methyltransferase 1
Aliases PRMT4; Histone-arginine methyltransferase CARM1
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CARM1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCARM1
Namecoactivator-associated arginine methyltransferase 1
Aliases PRMT4; Histone-arginine methyltransferase CARM1
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CARM1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCARM1
Namecoactivator-associated arginine methyltransferase 1
Aliases PRMT4; Histone-arginine methyltransferase CARM1
Chromosomal Location19p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CARM1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.